InteRNA, Radboud University Collaborate on miRNA Rx for Prostate Cancer | GenomeWeb

InteRNA Technologies and Radboud University Nijmegen Medical Centre said this week that they have agreed to collaborate on the development of microRNA-based therapeutics for prostate cancer.

Under the research arrangement, InteRNA's lentiviral-based miRNA over-expression library "will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer," the partners said.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.